In young mice with MC38 tumors, anti-PD-L1 therapy can increase the infiltration and function of tumor-infiltrating CD8+ T cells, CD4+ Tcon cells, and tumor antigen-specific CD8+ T cells, resulting in a robust antitumor response. This evidence concerns the gene CD8A and neoplasm.